Document Detail

Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate.
MedLine Citation:
PMID:  10852474     Owner:  NLM     Status:  MEDLINE    
Angiogenesis during luteal development is essential for normal lutein cell function, but the control of this process and the relationships between the steroidogenic and endothelial cells have still to be elucidated. The aim of this study was to: 1) quantify endothelial cell proliferation throughout the luteal phase of the marmoset ovulatory cycle; 2) determine the effect of gonadotropin withdrawal using GnRH antagonist treatment on the early luteal phase angiogenesis peak; and 3) describe the resultant morphological changes in the corpus luteum (CL). Ovaries were collected during the early, mid-, and late luteal phase, and changes in angiogenic activity were determined by quantification of bromodeoxyuridine incorporation. Animals were treated with a GnRH antagonist, on luteal days 1 and 2, and ovaries were collected on day 3. A proliferation index was obtained by counting the number of bromodeoxyuridine immunopositive cells in luteal sections. Cell proliferation was maximal in the early luteal phase and fell significantly in the mid- and late CL. GnRH antagonist treatment reduced the early luteal phase proliferation peak by 90%, suppressed plasma progesterone, and severely disrupted lutein cell morphology. These results demonstrate that the intense angiogenesis in the early primate CL is dependent on gonadotropin stimulation of lutein cells.
S E Dickson; H M Fraser
Related Documents :
9580944 - Autocrine/paracrine regulation of normal human corpus luteum development.
15817664 - Follicular cells acquire sertoli cell characteristics after oocyte loss.
2249634 - Estrogen regulation of thecal cell steroidogenesis and differentiation: thecal cell-gra...
1172304 - The influence of oestradiol benzoate and progesterone on the secretory activity of the ...
2366004 - Expression of 38-kd cell-surface glycoprotein in transformed human keratinocyte cell li...
21530604 - 16-hydroxycleroda-3,13-dien-15,16-olide deregulates pi3k and aurora b activities that i...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  85     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-06-23     Completed Date:  2000-06-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2339-44     Citation Subset:  AIM; IM    
Medical Research Council Human Reproductive Sciences Unit, Centre for Reproductive Biology, Edinburgh, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Division / drug effects
Corpus Luteum / blood supply*
Endothelium, Vascular / cytology*,  drug effects,  physiology
Gonadotropin-Releasing Hormone / antagonists & inhibitors
Hormone Antagonists / pharmacology*
Luteal Phase
Mitotic Index / drug effects
Neovascularization, Physiologic / drug effects*
Oligopeptides / pharmacology*
Progesterone / blood
Reg. No./Substance:
0/Hormone Antagonists; 0/Oligopeptides; 151272-78-5/antarelix; 33515-09-2/Gonadotropin-Releasing Hormone; 57-83-0/Progesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Changes in endometrial PTEN expression throughout the human menstrual cycle.
Next Document:  Expression of the heme oxygenase-carbon monoxide signalling system in human placenta.